Abstract
Herein, we present an overview on the current status of the characterization techniques and methodologies used to study the physicochemical descriptors that influence the final clinical performance of a given nanomedicine. The described techniques were selected based on their suitability to operate under relevant “native” conditions that mimic the physiological environment. Special emphasis is placed on those techniques that hold a greater potential to unravel dynamic, structural, and compositional features of soft organic nanomedicines relevant to the ability to bypass biological barriers, and hence allow for the rational design of drug delivery platforms with improved biological output.
Keywords: Nanomedicines, drug delivery systems, biological barriers, characterization techniques, polymer therapeutics.
Current Pharmaceutical Design
Title:Relevant Physicochemical Descriptors of “Soft Nanomedicines” to Bypass Biological Barriers
Volume: 22 Issue: 9
Author(s): Amaya Nino-Pariente, Vicent J. Nebot and Maria J. Vicent
Affiliation:
Keywords: Nanomedicines, drug delivery systems, biological barriers, characterization techniques, polymer therapeutics.
Abstract: Herein, we present an overview on the current status of the characterization techniques and methodologies used to study the physicochemical descriptors that influence the final clinical performance of a given nanomedicine. The described techniques were selected based on their suitability to operate under relevant “native” conditions that mimic the physiological environment. Special emphasis is placed on those techniques that hold a greater potential to unravel dynamic, structural, and compositional features of soft organic nanomedicines relevant to the ability to bypass biological barriers, and hence allow for the rational design of drug delivery platforms with improved biological output.
Export Options
About this article
Cite this article as:
Nino-Pariente Amaya, Nebot J. Vicent and Vicent J. Maria, Relevant Physicochemical Descriptors of “Soft Nanomedicines” to Bypass Biological Barriers, Current Pharmaceutical Design 2016; 22 (9) . https://dx.doi.org/10.2174/1381612822666151216152143
DOI https://dx.doi.org/10.2174/1381612822666151216152143 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Products as Modulators of Spermatogenesis: The Search for a Male Contraceptive
Current Molecular Pharmacology Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Chemical Proteomics to Identify Molecular Targets of Small Compounds
Current Molecular Medicine Anticancer and Cytotoxic Activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2)Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Scaling Down SAGE: from miniSAGE to microSAGE
Current Pharmaceutical Biotechnology Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands
Current Drug Targets Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design Anti-Cancer / Anti-Tumor
Current Bioactive Compounds The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews ATP Synthesis Revisited: New Avenues for the Management of Mitochondrial Diseases
Current Pharmaceutical Design Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Current Diabetes Reviews Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients
Cardiovascular & Hematological Disorders-Drug Targets Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology
Current Pharmaceutical Design Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets Cyclic Peptide Containing Hydrophobic and Positively Charged Residues as a Drug Delivery System for Curcumin
Current Drug Delivery Oral Chemotherapy in Elderly Women with Metastatic Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry